Stay informed with the latest company announcements, scientific publications, clinical milestones, media coverage, conferences, partnerships, and events from Helio Genomics.
Our landmark CLiMB trial — the largest prospective, multicenter U.S. study of its kind — is now peer-reviewed and published, demonstrating HelioLiver's superior sensitivity for early-stage HCC versus ultrasound.
Read Full Storycitybiz reports on Helio appointing Parminder Bhatia, SVP of AI at Edwards Lifesciences, to its Board of Directors, as it expands its platform for early cancer detection.
Read more360Dx reports Helio Genomics has appointed Parminder Bhatia, SVP of AI at Edwards Lifesciences and former Chief AI Officer at GE HealthCare, to its board.
Read moreThird News covered Helio Genomics appointing Parminder Bhatia to its Board of Directors as a strategic addition to its early-detection mission.
Read moreHelio appoints Parminder Bhatia — SVP of AI at Edwards Lifesciences and former Chief AI Officer at GE HealthCare — to its Board of Directors.
Read moreHelio CEO Bharat Tewarie joins the Diagnosing Dx podcast on why liver cancer screening must move beyond ultrasound toward AI-powered multiomics.
Read moreU.S. News & World Report on how GLP-1 drugs like Ozempic may lower the risk of some cancers, including liver cancer — and why early detection still matters.
Read moreDeciBio’s May 2026 Liquid Biopsy Round-Up features Helio’s Syneos Health partnership to expand HelioLiver, alongside GRAIL, Natera, Guardant, and Foundation Medicine.
Read moreTransparency Market Research projects the IVD market will reach $253.8B by 2036 — and names Helio’s Syneos Health partnership among its key developments.
Read moreHow rural healthcare is adopting collaborative, technology-enabled models for earlier detection and better outcomes.
Read moreHelio Genomics partnered with Syneos Health to drive adoption of its HelioLiver test for early HCC detection.
Read moreA strategic commercial partnership with Syneos Health to accelerate nationwide adoption of HelioLiver™.
Read moreHelio broadens access to HelioLiver through Quest Diagnostics’ nationwide network of patient service centers.
Read moreHelio joins the Rural Health Transformation Collaborative, co-chaired by Microsoft, to expand rural early detection.
Read moreMedPage Today’s GI news roundup notes HelioLiver Dx showed superior sensitivity and non-inferior specificity vs ultrasound, per the Journal of Hepatology.
Read moreAchyut Saroj uses the “Johari Window” to explain how HelioLiver’s multi-analyte, blood-based approach is shrinking the blind spot in liver cancer surveillance.
Read moreIn the landmark CLiMB study, HelioLiver™ showed superior sensitivity to ultrasound for detecting early-stage HCC in patients with cirrhosis.
Read morePublished in the Journal of Hepatology: HelioLiver detects more early HCC than ultrasound in cirrhosis (47.8% vs 28.3%; 28.6% vs 0% for lesions under 2 cm).
Read moreHelio’s CEO reflects on the landmark CLiMB study and what earlier liver cancer detection means for patients.
Read moreA new partnership with Syneos Health to expand access to the HelioLiver blood test and speed up adoption.
Read moreA new partnership to expand commercialization of the blood-based HelioLiver test for early HCC detection.
Read moreA strategic collaboration to boost adoption of HelioLiver, the AI blood test for early liver cancer detection.
Read moreOncData’s Exploring AI in Oncology: Helio CEO Bharat Tewarie on HelioLiver’s role alongside ultrasound and MRI, and barriers to adoption.
Read moreHelio appoints John Doyle — Microsoft’s Global CTO for Healthcare & Life Sciences — to its Board, strengthening governance and innovation strategy.
Read moreAny provider with a Quest account can order HelioLiver, leveraging Quest’s ~7,700 U.S. patient service centers for early liver cancer detection.
Read moreHelio supported an ALF Congressional briefing at the Rayburn House Office Building in Washington, D.C., bringing together experts, advocates, and policymakers.
Read moreIntegrating the LiverTrace™ blood test with LiverRight’s National Virtual Clinic — same-week access to board-certified hepatologists in all 50 states.
Read moreALF and Helio bring LiverTrace — a convenient at-home blood test for early liver cancer detection — to millions of at-risk Americans.
Read moreResults from three cancer-detection studies at DDW 2025, including a Monte Carlo simulation (Dr. Amit Singal) showing HelioLiver Dx detects a high proportion of early-stage HCC.
Read moreHelioLiver passed its CLiMB co-primary and secondary endpoints vs ultrasound; Helio’s methylation score showed prognostic utility. Featuring Dr. Van Etten.
Read moreDr. Richard Van Etten will present HelioLiver’s superior performance over ultrasound for early HCC detection at AASLD 2024 in San Diego.
Read moreWith Ochsner Health, Helio’s cfDNA methylation prognostic score outperformed ALBI, GALAD, MELD, Child-Pugh and AFP — awarded a top-three abstract.
Read moreHelio’s MESA approach — combining cfDNA fragmentomics and methylation on the ECLIPSE platform — reaches a median AUC of 0.91 for early colon cancer detection.
Read moreCEO Justin Chen Li is invited to the Leadership Board of the Terasaki Institute for Biomedical Innovation at UCLA, bringing early-detection expertise to its innovation strategy.
Read moreHelio names Eric A. Ariazi, Ph.D., a translational cancer biologist with 25+ years in precision oncology and liquid biopsy assay development, as Chief Development Officer.
Read moreHelio completes its separation from parent company Laboratory for Advanced Medicine (LAM), becoming a standalone entity focused on commercializing HelioLiver Dx.
Read moreLabMedica covers Helio’s CLiMB results showing the AI-powered HelioLiver Dx blood test detects HCC earlier and more sensitively than ultrasound.
Read morePivotal CLiMB data presented at the EASL Congress 2024 show HelioLiver Dx met its endpoints with superior sensitivity and non-inferior specificity versus ultrasound.
Read moreHelio’s Chief Medical Advisor, Dr. Richard Van Etten, will present late-breaking CLiMB data at the EASL Congress 2024 in Milan.
Read moreHelio names Gary Frazier — founder of Worksite Labs and OM Healthcare — as Chief Growth Officer, adding deep healthcare strategy expertise.
Read morePublished in Genome Medicine: a Helio and UC Irvine study shows MESA of cfDNA improves non-invasive colorectal cancer detection over single-modality approaches.
Read moreHelioLiver was named to PM360’s 11th Annual Innovations Issue, selected in the Products category among the year’s most groundbreaking life-sciences advancements.
Read moreHelio CEO Justin Chen Li on why liver cancer — rising in frequency yet highly survivable when caught early — deserves the awareness spotlight. Featured in DOTmed.
Read moreFrost & Sullivan named Helio its North American Company of the Year in Liver Cancer Early Detection with Liquid Biopsy — its top honor.
Read moreThe Internet Marketing Association (IMA) named Helio Genomics Healthcare Technology of the Year at its annual IMPACT Awards.
Read moreJoyce Cheung, Head of Commercialization at Helio Genomics, received the IMA Women in Leadership Award at the annual IMPACT Awards.
Read moreHelio CEO Justin Chen Li was named among five honorees at the Orange County Business Journal’s 8th annual Innovator of the Year Awards.
Read moreDhruvajyoti (Dhruv) Roy, Ph.D., Director of Technology at Helio Genomics, joined the Editorial Advisory Board of the oncology journal Onco’Zine.
Read moreThe American Medical Association issued a new Category I CPT® code for HelioLiver, establishing a reimbursement pathway for broader access to the liver-cancer blood test.
Read moreA Nature feature on how Helio’s ECLIPSE platform reads cell-free DNA methylation to find hepatocellular carcinoma earlier — and what that could mean for more accessible cancer screening.
Read moreHelioLiver™ was named Best New Biopsy Technology Solution in the 2022 MedTech Breakthrough Awards — Helio’s second consecutive win.
Read moreHelio Health and Fulgent Genetics launched HelioLiver™ — a multi-analyte blood test detecting liver cancer at its earliest stages (76% sensitivity, 91% specificity) from a simple blood draw.
Read moreENCORE data at The Liver Meeting 2021: at 91% specificity, HelioLiver showed 76% early-stage and 85% overall sensitivity, outperforming AFP and GALAD.
Read moreHelio Health and Fulgent announced a late-breaking HelioLiver poster at The Liver Meeting 2021 (AASLD), presented by David J. Taggart, PhD.
Read moreFulgent and Helio entered a strategic partnership — including a strategic investment — to commercialize Helio’s cfDNA methylation blood tests, starting with HelioLiver.
Read moreFUJIFILM and Helio Health announced a collaboration combining the HelioLiver Test with Fujifilm’s 510(k)-cleared µTASWako® i30 biomarker system.
Read moreHelio Health was named a winner in the fifth annual MedTech Breakthrough Awards, receiving Best New Technology Solution – Diagnostic.
Read moreHelio Health and China’s National Cancer Center won a Ministry of Science and Technology grant for a ~3,000-subject real-world screening study.
Read moreWatch the Helio Genomics fireside chat webcast at the 2021 BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
Read moreA thought-leadership review by Helio’s Dhruvajyoti Roy, Ph.D. on how ctDNA methylation is emerging as a promising, non-invasive approach to detect cancer early.
Read moreGEN profiled LAM — Helio’s predecessor — and new CEO Kenneth Chahine, PhD, JD, ahead of its first liquid biopsy for early-stage liver cancer.
Read moreMedical Xpress on a Science Translational Medicine study pairing ML with ctDNA methylation for colorectal cancer — 87.5% sensitivity, 89.9% specificity.
Read moreClinical OMICs on ctDNA methylation markers for colorectal cancer — a single marker reached 89.7% sensitivity and 86.8% specificity.
Read morePrecision Oncology News: ctDNA methylation may aid colorectal cancer diagnosis; LAM [now Helio Genomics] is commercializing the test.
Read moreCheddar: LAM (now Helio Genomics) raised $86M to develop its liver cancer blood test; CEO Kenneth Chahine discussed the raise.
Read moreOrange County Business Journal on LAM (now Helio Genomics): new CEO Chahine, an FDA breakthrough-designated liver cancer test, and $86M raised.
Read moreEndpoints News profiles Kenneth Chahine as he becomes CEO of LAM (now Helio Genomics) to lead its methylation-based liquid biopsy.
Read moreA Technology Networks Q&A with LAM’s Richard Brand and Dhruvajyoti Roy on cfDNA methylation, IvyGene, and new NPC data (97% sensitivity).
Read moreFiOS1 News on the IvyGene test — from LAM (now Helio Genomics) — which could detect cancer as early as stage one.
Read moreThe City of Mission, Texas authorized IvyGene tests — from LAM (now Helio Genomics) — to screen firefighters for colon, liver and lung cancer.
Read moreSan Diego Union-Tribune on a UC San Diego blood test detecting liver cancer via DNA methylation — AUC 0.969 vs 0.816 for AFP.
Read moreUC San Diego on a blood-based ctDNA methylation method for early detection of hepatocellular carcinoma, published in Nature Materials.
Read moreNo articles match your search.
Join the Helio Genomics team at conferences, symposiums, and webinars across the field — or revisit where we've recently been.
We're finalising our next conferences, symposiums, and webinars. Check back shortly for where to find the Helio Genomics team next.
Helio showcased results from three cancer detection studies at the 2025 Digestive Disease Week Conference.
More InfoThe presentation will dive into promising findings and their significant impact on the liver cancer landscape.
More Info